医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Biological Industries Announces Poster Presentation at International Society for Cell Therapy Annual Meeting in Singapore

2016年05月23日 PM09:45
このエントリーをはてなブックマークに追加


 

KIBBUTZ BEIT HAEMEK, Israel & CROMWELL, Conn.

Biological Industries (“BI”; www.bioind.com), a leading developer and manufacturer of cell culture media, molecular biology tools, human cytogenetics media, and custom media manufacturing services, is participating and making a poster presentation at ISCT 2016, the annual meeting of the International Society for Cellular Therapy, 25-28 May, in Singapore.

The poster presentation, “A Novel Set of Serum-Free, Xeno-Free Differentiation Media for Adipogenesis, Osteogenesis and Chondrogenesis of Human Mesenchymal Stem Cells from Various Tissue Sources,” will be presented by BI’s R&D Product Manager, Mira Genser-Nir, Ph.D.

Presentation Details

  • Abstract Number: 205
  • Presentation Title: A Novel Set of Serum-Free, Xeno-Free Differentiation Media for Adipogenesis, Osteogenesis and Chondrogenesis of Human Mesenchymal Stem Cells from Various Tissue Sources
  • The poster will be available for the duration of the conference

“Human mesenchymal stem cells (hMSCs) are multipotent adult stem cells that can be isolated from various tissues as well as generated in vitro from hESCs and iPS cells,” observed Dr. Genser-Nir. “In order for hMSCs to become the cells of choice for use in regenerative medicine and drug screening, the culture conditions must be improved and differentiation potential is required. We feel that this paper represents a big step toward addressing these issues.”

BI will also have a booth at the conference, #C07-C09.

More information on ISCT 2016 is available at www.isct2016.com.

About Biological Industries

BIOLOGICAL INDUSTRIES (BI) develops, manufactures, and supplies life science products to universities, government research, healthcare institutions, and the biopharmaceutical industry. For over 30 years, BI has been working alongside some of the world’s leading academic researchers and institutes in the development of cell culture media, stem cell reagents, and molecular biology tools. BI also offers custom media development and manufacturing services through its ISO 13485:2003 certified cGMP facilities. BI currently supplies products to researchers and clinicians in over 40 countries with products currently in clinical trials. BI is leveraging their industry-leading experience in cell culture media and pluripotent stem cell technology to help facilitate breakthroughs in stem cell research worldwide. BI is committed to a Culture of Excellence by providing the highest quality reagents and cost-effective, innovative products and services tailored to a customer’s specific needs.

To receive ongoing BI communications, please join our email list or connect with the company on LinkedIn, Twitter, and Facebook.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160523005816/en/

CONTACT

Media:
Gotham
Communications
for Biological Industries
Bill
Douglass
, +1-646-504-0890
bill@gothamcomm.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM(ブリガチニブ)のピボタル第2相ALTA試験の最新データを発表
  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″
  • Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
  • Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
  • 武田呈报ALUNBRIGTM (brigatinib)治疗ALK阳性非小细胞肺癌枢纽性2期ALTA试验的更新结果